Pluri Inc Quick Ratio (PLUR) starting from the fourth quarter 2026 to fourth quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Pluri Inc   (NASDAQ: PLUR)

Pluri Inc 's Quick Ratio

PLUR's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Pluri Inc 's Cash & cash equivalent grew by 40.81 % in the Q4 2026 sequentially, faster than Current Liabilities, this led to improvement in Pluri Inc 's Quick Ratio to 0.4, Quick Ratio remained below Pluri Inc average.

Within Biotechnology & Pharmaceuticals industry 128 other companies have achieved higher Quick Ratio than Pluri Inc in fourth quarter 2026. While Quick Ratio total ranking has improved so far during the Q4 2026 to 2661, from total ranking in the third quarter 2026 at 2907.

Explain Quick Ratio?
How much Cash & cash equivalents PLUR´s has?
What are PLUR´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

PLUR Quick Ratio (Jun 30 2026)
Q4		 (Mar 31 2026)
Q3		 (Dec 31 2025)
Q2		 (Sep 30 2025)
Q1		 (Jun 30 2025)
Q4
Y / Y Current Liabilities Change 1.21 % 461.02 % 625.82 % 601.72 % 625.82 %
Y / Y Cash & cash equivalent Change -36.32 % -64.52 % -31.26 % 370.79 % -31.26 %
Quick Ratio MRQ 0.4 0.29 0.64 0.47 0.64
PLUR's Total Ranking # 2661 # 2907 # 1717 # 2029 # 1796
Seq. Current Liabilities Change 2.23 % -1 % 0.52 % -0.52 % 466.66 %
Seq. Cash & cash equivalent Change 40.81 % -54.78 % 36.91 % -26.96 % -21.54 %



Quick Ratio fourth quarter 2026 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 129
Healthcare Sector # 755
Overall Market # 2661


Quick Ratio Statistics
High Average Low
21.22 4.2 0.29
(Jun 30 2011)   (Mar 31 2026)




Financial Statements
Pluri Inc 's Current Liabilities $ 33 Millions Visit PLUR's Balance sheet
Pluri Inc 's Cash & cash equivalent $ 13 Millions Visit PLUR's Balance sheet
Source of PLUR's Sales Visit PLUR's Sales by Geography


Cumulative Pluri Inc 's Quick Ratio

PLUR's Quick Ratio for the trailling 12 Months

PLUR Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 174.51 % 571.09 % 469.02 % 289.11 % 148.74 %
Y / Y Cash & cash equivalent TTM Growth -27.42 % -26.65 % 17.52 % 101.49 % 67.93 %
Quick Ratio TTM 0.45 0.51 0.81 1.23 1.7
Total Ranking TTM # 4110 # 3165 # 2130 # 2905 # 3007
Seq. Current Liabilities TTM Growth 0.3 % 25.65 % 37.34 % 58.59 % 145.21 %
Seq. Cash & cash equivalent TTM Growth -11.41 % -20.53 % -10.2 % 14.81 % -10.48 %

Quick ratio ranking by company, industry and sector >> Back to PLUR Financial Strength Comparisons >> Go to Compare PLUR Quick Ratio to its Competitors

On the trailing twelve months basis Due to rise in Current Liabilities in the Q4 2026 to $32.72 millions, cumulative Quick Ratio decreased to 0.45 below the Pluri Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 142 other companies have achieved higher Quick Ratio than Pluri Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2026 from 3165 to 4110.

Explain Quick Ratio?
How much Cash & cash equivalents PLUR´s has?
What are PLUR´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 143
Healthcare Sector # 908
Within the Market # 4110


trailing twelve months Quick Ratio Statistics
High Average Low
7.15 3.85 0.45
(Dec 31 2015)   (Jun 30 2026)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Biotechnology & Pharmaceuticals Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Amgen Inc   1.07 $ 27,404.000  Millions$ 25,502.000  Millions
Aligos Therapeutics Inc   1.07 $ 30.381  Millions$ 28.343  Millions
Vaxart Inc   1.05 $ 77.058  Millions$ 73.108  Millions
Iovance Biotherapeutics inc   1.04 $ 110.768  Millions$ 106.848  Millions
Liminatus Pharma Inc   0.99 $ 3.017  Millions$ 3.040  Millions
Elutia Inc   0.95 $ 19.896  Millions$ 21.045  Millions
Jasper Therapeutics Inc   0.93 $ 7.314  Millions$ 7.845  Millions
Protalix Biotherapeutics inc   0.90 $ 28.140  Millions$ 31.391  Millions
Vivosim Labs Inc   0.88 $ 1.670  Millions$ 1.893  Millions
Senti Biosciences Holdings Inc   0.83 $ 13.124  Millions$ 15.765  Millions
Pelthos Therapeutics Inc   0.78 $ 24.776  Millions$ 31.959  Millions
Ocugen Inc   0.75 $ 100.051  Millions$ 133.080  Millions
Sab Biotherapeutics Inc   0.71 $ 8.267  Millions$ 11.705  Millions
Vaxcyte Inc   0.68 $ 183.190  Millions$ 271.277  Millions
Halozyme Therapeutics Inc   0.61 $ 231.081  Millions$ 375.965  Millions
Silexion Therapeutics Corp  0.57 $ 2.258  Millions$ 3.976  Millions
Atlantic Coastal Acquisition Corp Ii  0.52 $ 4.291  Millions$ 8.225  Millions
Surrozen Inc   0.50 $ 102.039  Millions$ 203.292  Millions
Pluri Inc   0.40 $ 13.126  Millions$ 32.719  Millions
Outlook Therapeutics Inc   0.39 $ 11.242  Millions$ 28.679  Millions
Neurocrine Biosciences Inc   0.37 $ 390.500  Millions$ 1,046.100  Millions
Curis Inc   0.37 $ 5.100  Millions$ 13.675  Millions
Creative Medical Technology Holdings Inc   0.36 $ 0.250  Millions$ 0.699  Millions
Xtant Medical Holdings Inc   0.33 $ 9.870  Millions$ 29.963  Millions
Champions Oncology Inc   0.23 $ 4.358  Millions$ 18.729  Millions
ADAPTIN BIO, INC.  0.22 $ 0.670  Millions$ 3.036  Millions
Armata Pharmaceuticals Inc   0.10 $ 23.952  Millions$ 250.199  Millions
Agenus Inc  0.08 $ 18.738  Millions$ 231.820  Millions

Date modified: 2026-09-18T18:01:05+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.